查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1801872

血浆分馏市场机会、成长动力、产业趋势分析及 2025 - 2034 年预测

Plasma Fractionation Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
出版日期: | 出版商: Global Market Insights Inc. | 英文 140 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2024年，全球血浆分离市场规模达337亿美元，预计2034年将以6.6%的复合年增长率成长，达到653亿美元。这项市场扩张的驱动力在于：免疫球蛋白在各种治疗方案中的应用日益广泛，对高端医疗保健方案的需求日益增长，以及分离技术的持续改进。确诊患有遗传和免疫疾病的患者数量显着增加，推动了血浆衍生疗法的普及。随着诊断技术的进步，慢性疾病的可近性不断提升，患者获得血浆蛋白治疗的机会也日益增加。血浆分离，即从捐献血液中提取和分离关键蛋白质的工业工艺，正是这项变革的核心。

血浆分馏市场 - IMG1

血浆蛋白（例如白蛋白和凝血因子）在多种疾病的治疗中至关重要。自体免疫疾病和遗传性疾病的发生率不断上升，促使这些疗法的应用范围不断扩大。研发投入的增加进一步推动了不同医疗保健领域血浆疗法的创新。从管理免疫缺陷到治疗出血性疾病，血浆成分的应用范围正在显着扩大，有助于在预测期内保持稳定的需求。

市场范围
起始年份 2024
预测年份 2025-2034
起始值 337亿美元
预测值 653亿美元
复合年增长率 6.6%

2024年，免疫球蛋白细分市场占据46.8%的市场份额，反映出对用于治疗各种健康状况的血浆疗法的强劲需求。受免疫和神经系统疾病患者数量的增加所推动，该细分市场的使用量正在激增。静脉注射免疫球蛋白（IVIg）在临床环境中的超说明书应用日益增多，以及其在治疗格林-巴利综合症和川崎病等疾病方面的广泛应用，巩固了其在市场上的主导地位，并支持了其持续增长。

2024年，冷乙醇分馏技术占47.9%的市占率。由于其高效、经济且能够生产高纯度血浆蛋白，该技术仍然是大型血浆处理设施的标准。它适用于同时提取多种蛋白质，并兼具安全性和提取性能。其在分离关键血浆成分（例如免疫球蛋白和白蛋白）方面应用尤为广泛。

2024年，美国血浆分离市场规模达104亿美元。凭藉强大的医疗基础设施、血浆疗法的认知度以及广泛的捐赠中心，美国在该领域保持领先地位。慢性病盛行率的上升以及免疫球蛋白和凝血因子在临床治疗中的常规使用，扩大了对血浆衍生产品的需求。随着越来越多的患者需要长期治疗，对可靠血浆蛋白供应的需求持续攀升，从而增强了美国市场的实力。

活跃于血浆分离市场的主要公司包括武田製药、Kedrion Biopharma、Grifols、Prothya Biosolutions、GC Biopharma、SK Plasma、Kamada Pharmaceuticals、LFB Group、VIRCHOW BIOTECH PRIVATE LIMITED、日本血液製品组织 (JB)、Intas Pharmaceticals、TECH PRIVATE LIMITED、日本血液製品组织 (JB)、Intas Pharmaceuticals、Intas Pharmauticals、Octibu Group。为了在全球血浆分离市场站稳脚跟，领先的公司正在实施以产能扩张、策略合作和加工方法创新为重点的策略。他们正在加大研发投入，探索血浆衍生蛋白的新型治疗应用。许多公司也与医疗保健提供者和政府机构签订了长期协议，以确保稳定的供需。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

  • 产业生态系统分析
  • 产业衝击力
    • 成长动力
      • 对先进治疗方案的需求不断增长
      • 免疫球蛋白在各种治疗应用的应用日益增多
      • 呼吸系统疾病和遗传疾病的盛行率不断上升
      • 血浆分离技术进步
    • 产业陷阱与挑战
      • 严格的监理政策
      • 替代方案的出现
    • 市场机会
      • 政府有利于自给自足的策略
      • 血浆衍生疗法的研发活动日益增多
  • 成长潜力分析
  • 监管格局
    • 北美洲
    • 欧洲
    • 亚太地区
  • 技术进步
    • 当前的技术趋势
    • 新兴技术
  • 血浆分离过程概述
  • 价值链分析
  • 2024年各地区白蛋白销量
  • 市场演变与历史背景
  • 波特的分析
  • PESTEL分析
  • 未来市场趋势
  • 差距分析

第四章：竞争格局

  • 介绍
  • 公司市占率分析
    • 全球的
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • MEA
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 关键进展
    • 併购
    • 伙伴关係和合作
    • 新产品发布
    • 扩张计划

第五章：市场估计与预测：按产品，2021 - 2034 年

  • 主要趋势
  • 免疫球蛋白
    • 静脉注射免疫球蛋白
    • 皮下免疫球蛋白
    • 其他免疫球蛋白
  • 凝血因子
    • 第八因子
    • 凝血因子IX
    • 凝血酶原复合物浓缩物
    • 血管性血友病因子
    • 纤维蛋白原浓缩物
    • 其他凝血因子浓缩物
  • 白蛋白
  • 蛋白酶抑制剂
  • 其他血浆产品

第六章：市场估计与预测：依方法，2021 - 2034 年

  • 主要趋势
  • 冷乙醇分馏
  • 色谱法
  • 离心
  • 其他方法

第七章：市场估计与预测：按应用，2021 - 2034 年

  • 主要趋势
  • 免疫学
  • 神经病学
  • 血液学
  • 肺部疾病学
  • 肿瘤学
  • 其他应用

第八章：市场估计与预测：依最终用途，2021 - 2034 年

  • 主要趋势
  • 医院和诊所
  • 临床研究实验室
  • 其他最终用途

第九章：市场估计与预测：按地区，2021 - 2034 年

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第十章：公司简介

  • LFB Group
  • CSL
  • GC Biopharma
  • Grifols
  • Intas Pharmaceuticals
  • Japan Blood Products Organization (JB)
  • Kamada Pharmaceuticals
  • Kedrion Biopharma
  • Octapharma
  • Prothya Biosolutions
  • SK Plasma
  • Taibang Biologic Group
  • Takeda
  • VIRCHOW BIOTECH PRIVATE LIMITED
简介目录
Product Code: 14588

The Global Plasma Fractionation Market was valued at USD 33.7 billion in 2024 and is estimated to grow at a CAGR of 6.6% to reach USD 65.3 billion by 2034. This market expansion is being shaped by the increasing usage of immunoglobulins across a range of therapeutic treatments, higher demand for sophisticated healthcare options, and continuous improvements in fractionation technologies. A significant rise in the number of patients diagnosed with genetic and immunological conditions is pushing the adoption of plasma-derived therapies. With chronic illnesses becoming more detectable through improved diagnostics, patient access to treatments requiring plasma proteins is increasing. Plasma fractionation, the industrial process used to extract and isolate critical proteins from donated blood, is at the center of this transformation.

Plasma Fractionation Market - IMG1

Plasma proteins such as albumin and coagulation factors are essential in the treatment of multiple disorders. The growing frequency of autoimmune and inherited diseases is contributing to the broader use of these therapies. Increased R&D investments are further driving innovations in plasma-based treatments across diverse healthcare segments. From managing immune deficiencies to treating bleeding disorders, the applications of fractionated plasma components are expanding significantly, helping to fuel consistent demand through the forecast period.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$33.7 Billion
Forecast Value$65.3 Billion
CAGR6.6%

The immunoglobulins segment accounted for a 46.8% share in 2024, reflecting strong demand for plasma-based therapies used in treating a broad range of health conditions. The segment is witnessing a surge in usage driven by a growing number of immunological and neurological diseases. Increasing off-label application of IVIg in clinical settings and its wider adoption for managing conditions like Guillain-Barre syndrome and Kawasaki disease are contributing to its dominant position in the market and supporting sustained growth.

The cold ethanol fractionation segment held a 47.9% share in 2024. The technique remains a standard in large-scale plasma processing facilities due to its efficiency, cost-effectiveness, and ability to yield high-purity plasma proteins. It is favored for extracting multiple protein types simultaneously and offers an optimal mix of safety and extraction performance. Its use is especially widespread for isolating key plasma components such as immunoglobulins and albumin.

U.S. Plasma Fractionation Market was valued at USD 10.4 billion in 2024. The country maintains a leadership position in this sector due to strong healthcare infrastructure, high awareness of plasma-based therapies, and widespread availability of donation centers. Increasing prevalence of chronic conditions and the routine use of immunoglobulins and coagulation factors in clinical care have amplified the demand for plasma-derived products. As more patients require long-term therapies, the need for reliable plasma protein supply continues to climb, bolstering U.S. market strength.

Key companies active in the Plasma Fractionation Market include Takeda, Kedrion Biopharma, Grifols, Prothya Biosolutions, GC Biopharma, SK Plasma, Kamada Pharmaceuticals, LFB Group, VIRCHOW BIOTECH PRIVATE LIMITED, Japan Blood Products Organization (JB), Intas Pharmaceuticals, Octapharma, CSL, and Taibang Biologic Group. To secure a strong foothold in the Global Plasma Fractionation Market, leading companies are implementing strategies focused on capacity expansion, strategic collaborations, and innovation in processing methods. They are increasing investments in research and development to explore new therapeutic applications of plasma-derived proteins. Many firms are also forming long-term agreements with healthcare providers and government agencies to ensure consistent demand and supply.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definition
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Data mining sources
    • 1.3.1 Global
    • 1.3.2 Regional/Country
  • 1.4 Base estimates and calculations
    • 1.4.1 Base year calculation
    • 1.4.2 Key trends for market estimation
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
  • 1.6 Forecast model
  • 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis
  • 2.2 Key market trends
    • 2.2.1 Regional trends
    • 2.2.2 Product trends
    • 2.2.3 Method trends
    • 2.2.4 Application trends
    • 2.2.5 End use trends
  • 2.3 CXO perspectives: Strategic imperatives
    • 2.3.1 Key decision points for industry executives
    • 2.3.2 Critical success factors for market players
  • 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Growing demand for advanced treatment options
      • 3.2.1.2 Rising adoption of immunoglobulins in various therapeutic applications
      • 3.2.1.3 Increasing prevalence of respiratory and genetic disorders
      • 3.2.1.4 Technological advancements in plasma fractionation
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Stringent regulatory policies
      • 3.2.2.2 Emergence of alternative options
    • 3.2.3 Market opportunities
      • 3.2.3.1 Favourable government strategies for self-sufficiency
      • 3.2.3.2 Growing research and development activities for plasma-derived therapies
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
    • 3.4.1 North America
    • 3.4.2 Europe
    • 3.4.3 Asia Pacific
  • 3.5 Technological advancements
    • 3.5.1 Current technological trends
    • 3.5.2 Emerging technologies
  • 3.6 Plasma fractionation process overview
  • 3.7 Value chain analysis
  • 3.8 Albumin unit sales by region, 2024
  • 3.9 Market evolution and historical context
  • 3.10 Porter's analysis
  • 3.11 PESTEL analysis
  • 3.12 Future market trends
  • 3.13 Gap analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company market share analysis
    • 4.2.1 Global
    • 4.2.2 North America
    • 4.2.3 Europe
    • 4.2.4 Asia Pacific
    • 4.2.5 Latin America
    • 4.2.6 MEA
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Key developments
    • 4.6.1 Mergers and acquisitions
    • 4.6.2 Partnerships and collaborations
    • 4.6.3 New product launches
    • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Immunoglobulins
    • 5.2.1 Intravenous immunoglobulins
    • 5.2.2 Subcutaneous immunoglobulins
    • 5.2.3 Other immunoglobulins
  • 5.3 Coagulation factors
    • 5.3.1 Factor VIII
    • 5.3.2 Factor IX
    • 5.3.3 Prothrombin complex concentrates
    • 5.3.4 VON WILLEBRAND factor
    • 5.3.5 Fibrinogen concentrates
    • 5.3.6 Other coagulation factor concentrates
  • 5.4 Albumin
  • 5.5 Protease inhibitors
  • 5.6 Other plasma products

Chapter 6 Market Estimates and Forecast, By Method, 2021 - 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 Cold ethanol fractionation
  • 6.3 Chromatography
  • 6.4 Centrifugation
  • 6.5 Other methods

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Immunology
  • 7.3 Neurology
  • 7.4 Hematology
  • 7.5 Pulmonology
  • 7.6 Oncology
  • 7.7 Other applications

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospitals and clinics
  • 8.3 Clinical research laboratories
  • 8.4 Other end use

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE

Chapter 10 Company Profiles

  • 10.1 LFB Group
  • 10.2 CSL
  • 10.3 GC Biopharma
  • 10.4 Grifols
  • 10.5 Intas Pharmaceuticals
  • 10.6 Japan Blood Products Organization (JB)
  • 10.7 Kamada Pharmaceuticals
  • 10.8 Kedrion Biopharma
  • 10.9 Octapharma
  • 10.10 Prothya Biosolutions
  • 10.11 SK Plasma
  • 10.12 Taibang Biologic Group
  • 10.13 Takeda
  • 10.14 VIRCHOW BIOTECH PRIVATE LIMITED